Trial
NCT00363883
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Intervention
vorinostat
Why stopped
Trial stopped early for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-02-13